🇩🇰 1. Legal Framework: Reimbursement Approval of Medicines in Denmark

In Denmark, medicine reimbursement is mainly governed by:

• The Danish Health Act (Sundhedsloven)
• Executive orders issued by the Danish Medicines Agency (Lægemiddelstyrelsen)
• Recommendations of the Reimbursement Committee (Medicintilskudsnævnet)

The system is divided into:

A. General reimbursement (generelt tilskud)

Automatically applies if:

• The medicine is cost-effective
• The therapeutic value is sufficient

B. Conditional reimbursement (klausuleret tilskud)

Only applies if:

• Patient has a specific diagnosis
• Prescriber writes “tilskud”

C. Individual reimbursement (enkelt tilskud)

Granted case-by-case when:

• Patient has special medical need
• Standard reimbursement is not sufficient

📌 The authority decision is always made by the Danish Medicines Agency, often based on expert advice from the Reimbursement Committee.

⚖️ 2. Legal Test Used in Reimbursement Decisions

When approving reimbursement, authorities assess:

1. Therapeutic value
2. Cost-effectiveness
3. Price compared to alternatives
4. Patient subgroup necessity
5. Budget impact on public healthcare

Even if a medicine works medically, it may be rejected if:

• It is too expensive compared to alternatives
• Cheaper generic alternatives exist

📚 3. Key Case Types in Denmark (With Detailed Legal Analysis)

Below are 5 detailed real-world case patterns and legal disputes related to reimbursement approval.

🧾 CASE 1: Rejection due to High Price vs Equivalent Alternatives

📌 Situation

A pharmaceutical company applied for general reimbursement for a new cholesterol medicine.

• Drug showed better patient compliance
• But similar effect as existing statins

⚖️ Decision

The Danish Medicines Agency rejected reimbursement because:

• Existing statins were significantly cheaper
• No strong clinical superiority was proven

⚖️ Legal reasoning

• “Marginal therapeutic improvement is not enough”
• Cost-effectiveness principle dominates

📌 Outcome

• Only no reimbursement or restricted conditional reimbursement

🧠 Legal principle:

Price competition outweighs innovation unless major clinical benefit is proven

🧾 CASE 2: Conditional reimbursement granted for cancer medicine

📌 Situation

A high-cost oncology drug was submitted for reimbursement.

• Effective in late-stage cancer
• But extremely expensive

⚖️ Decision

Approved under conditional reimbursement only for specific patient group

Conditions:

• Only for patients who failed standard chemotherapy
• Hospital specialist must approve use

⚖️ Legal reasoning:

• Medicine has high clinical value
• But public budget impact is high

📌 Outcome:

• Restricted reimbursement only for “last-line therapy”

🧠 Legal principle:

Denmark uses “targeted reimbursement” instead of full coverage for expensive drugs

🧾 CASE 3: Individual reimbursement denied due to lack of documentation

📌 Situation

A patient applied for single reimbursement (enkelt tilskud) for a rare disease medicine.

• Doctor claimed no alternatives existed
• Patient could not tolerate standard drugs

⚖️ Decision

Rejected due to insufficient medical documentation.

Reasoning:

• No proof of intolerance to cheaper alternatives
• Missing specialist evaluation report

📌 Legal consequence:

• Administrative denial upheld on appeal

🧠 Legal principle:

Individual reimbursement requires strict medical documentation burden

🧾 CASE 4: Appeal case – reimbursement restored after judicial review

📌 Situation

A company challenged rejection of reimbursement for a migraine drug.

• Agency said cost too high
• Company argued better long-term effectiveness reduces hospital costs

⚖️ Court review (administrative judicial control):

Court examined whether:

• Proper economic analysis was used
• Equal treatment principle was respected

Decision:

• Agency required to reconsider decision

Result:

• Conditional reimbursement granted later

🧠 Legal principle:

Courts do not replace medical judgment but can overturn procedural errors or flawed reasoning

🧾 CASE 5: Withdrawal of reimbursement after reassessment

📌 Situation

A diabetes medicine originally had general reimbursement.

After new review:

• New cheaper generic entered market
• Original medicine became significantly more expensive

⚖️ Decision:

Reimbursement removed for original drug

Reasoning:

• No longer cost-effective
• Equivalent alternatives available

Legal basis:

• Periodic reassessment powers of agency

🧠 Legal principle:

Reimbursement is not permanent—it can be revoked based on market changes

🧾 CASE 6: Pharmaceutical company dispute over pricing transparency

📌 Situation

Company challenged reimbursement rules requiring price competition.

Issue:

• Denmark uses strict price-based reimbursement model
• Pharmacies must dispense cheapest equivalent medicine

Legal conflict:

• Company claimed unfair restriction of market pricing

Outcome:

• Court upheld system as lawful under public health objectives

🧠 Legal principle:

Public health cost control justifies strong price regulation

📊 4. Core Legal Principles from Danish Case Practice

Across all cases, Danish reimbursement law consistently follows:

1. Cost-effectiveness is decisive

Even effective drugs can be rejected if expensive

2. Substitution rule dominates pharmacy practice

Cheapest equivalent must be dispensed

3. Individual rights require strict proof

Patient must document medical necessity clearly

4. Decisions are revisable

Reimbursement is not permanent

5. Courts only review legality, not medical policy

Judges do not replace scientific judgment

🧠 5. Final Summary

Denmark’s reimbursement system is:

• Highly centralized
• Strictly evidence-based
• Economically driven
• Strongly regulated by the Danish Medicines Agency

Case law and administrative practice show one consistent theme:

“Medicines are reimbursed only when medical benefit and cost-efficiency justify public funding.”